{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:15:17Z","timestamp":1788365717159,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.029","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:15:34Z","timestamp":1781738134000},"page":"5302-5318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17\/IgA mucosal Immunity"],"prefix":"10.1016","volume":"34","author":[{"given":"Youssouf","family":"Sereme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Villeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Caboche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ikeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Beury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Maurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-2524","authenticated-orcid":false,"given":"Christophe","family":"Desterke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Born-Bony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rom\u00e9","family":"Voulhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8595-6970","authenticated-orcid":false,"given":"Jean-Michel","family":"Sallenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.029_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2017.21550","article-title":"The drug-resistant bacteria that pose the greatest health threats","volume":"543","author":"Willyard","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.029_bib2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ymthe.2026.06.029_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.029_bib4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3390\/ijms26052012","article-title":"Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations","volume":"26","author":"Santamarina-Fern\u00e1ndez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.029_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/vaccines10071100","article-title":"Pseudomonas aeruginosa: Recent Advances in Vaccine Development","volume":"10","author":"Killough","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.06.029_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4161\/hv.7.10.16369","article-title":"Recent developments for Pseudomonas vaccines","volume":"7","author":"Sharma","year":"2011","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.029_bib7","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3390\/cells9122617","article-title":"Understanding Pseudomonas aeruginosa\u2013Host Interactions: The Ongoing Quest for an Efficacious Vaccine","volume":"9","author":"Sainz-Mej\u00edas","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.06.029_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01295-3","article-title":"Implications of Non-Specific Effects for Testing, Approving, and Regulating Vaccines","volume":"46","author":"Benn","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2026.06.029_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2026.06.029_bib10","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.06.029_bib11","article-title":"Viral Live-Attenuated Vaccines (LAVs): Past and Future Directions","volume":"12","author":"Tang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.06.029_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008311","article-title":"A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa","volume":"16","author":"Cabral","year":"2020","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2026.06.029_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.201202-0182OC","article-title":"Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia","volume":"186","author":"Wu","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2026.06.029_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15480","article-title":"Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy","volume":"8","author":"Cabral","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.71.3.1453-1461.2003","article-title":"Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant","volume":"71","author":"Priebe","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1128\/IAI.70.3.1507-1517.2002","article-title":"Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine","volume":"70","author":"Priebe","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib17","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1038\/s41467-024-50843-7","article-title":"An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection","volume":"15","author":"Pigula","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib18","first-page":"e3857","article-title":"Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung","author":"Kirchner","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymthe.2026.06.029_bib19","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1128\/AEM.03609-12","article-title":"Direct assessment of metabolite utilization by Pseudomonas aeruginosa during growth on artificial sputum medium","volume":"79","author":"Behrends","year":"2013","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib20","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1002\/pmic.200401227","article-title":"Proteome analysis reveals adaptation of Pseudomonas aeruginosa to the cystic fibrosis lung environment","volume":"5","author":"Sriramulu","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.ymthe.2026.06.029_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406234121","article-title":"Improvement of a mouse infection model to capture Pseudomonas aeruginosa chronic physiology in cystic fibrosis","volume":"121","author":"Duncan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.029_bib22","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1093\/jac\/dkac320","article-title":"Clinically undetected polyclonal heteroresistance among Pseudomonas aeruginosa isolated from cystic fibrosis respiratory specimens","volume":"77","author":"Maxwell","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ymthe.2026.06.029_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/microorganisms10071269","article-title":"The Use of Artificial Sputum Media to Enhance Investigation and Subsequent Treatment of Cystic Fibrosis Bacterial Infections","volume":"10","author":"Aiyer","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ymthe.2026.06.029_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00250-21","article-title":"Impact of Artificial Sputum Medium Formulation on Pseudomonas aeruginosa Secondary Metabolite Production","volume":"203","author":"Neve","year":"2021","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib25","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1073\/pnas.1419677112","article-title":"Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum","volume":"112","author":"Turner","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.029_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tim.2016.01.008","article-title":"Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections","volume":"24","author":"Winstanley","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/jcm.33.1.37-40.1995","article-title":"Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild-type strains in respiratory infections in patients with cystic fibrosis","volume":"33","author":"Barth","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1574-6968.1992.tb05268.x","article-title":"Auxotrophy of Pseudomonas aeruginosa in cystic fibrosis","volume":"71","author":"Taylor","year":"1992","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.ymthe.2026.06.029_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2180-5-43","article-title":"Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India","volume":"5","author":"Agarwal","year":"2005","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat9691","article-title":"Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection","volume":"363","author":"Sweere","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.06.029_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00244","article-title":"Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections","volume":"11","author":"Secor","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/ismej.2008.109","article-title":"The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage","volume":"3","author":"Rice","year":"2009","journal-title":"ISME J."},{"key":"10.1016\/j.ymthe.2026.06.029_bib33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35101627","article-title":"Gene expression in Pseudomonas aeruginosa biofilms","volume":"413","author":"Whiteley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.029_bib34","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41467-024-51617-x","article-title":"Control of lysogeny and antiphage defense by a prophage-encoded kinase-phosphatase module","volume":"15","author":"Guo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ng.3148","article-title":"Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis","volume":"47","author":"Marvig","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.06.029_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1099\/jmm.0.05069-0","article-title":"Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"52","author":"H\u00e4u\u00dfler","year":"2003","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1086\/598644","article-title":"Small-Colony Variants of Pseudomonas aeruginosa in Cystic Fibrosis","volume":"29","author":"H\u00e4u\u00dfler","year":"1999","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/j.ymthe.2026.06.029_bib38","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2018.02.040","article-title":"Killed but metabolically active Pseudomonas aeruginosa -based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections","volume":"36","author":"Meynet","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.06.029_bib39","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.4049\/jimmunol.181.7.4965","article-title":"IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa","volume":"181","author":"Priebe","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities\u2014workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.029_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104585","article-title":"Mucosal vaccines for SARS-CoV-2: triumph of hope over experience","volume":"92","author":"Pilapitiya","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ymthe.2026.06.029_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.06.029_bib43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","article-title":"Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques","volume":"626","author":"McMahan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.029_bib44","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/vaccines11091427","article-title":"Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre\u2013Fusion Spike Glycoproteins Protects Non\u2013Human Primates against SARS-CoV-2 Infection","volume":"11","author":"Wang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ymthe.2026.06.029_bib45","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1038\/s41467-025-60726-0","article-title":"Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial","volume":"16","author":"Jeyanathan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/thoraxjnl-2017-210298","article-title":"Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway","volume":"73","author":"Saint-Criq","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.ymthe.2026.06.029_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01675","article-title":"Pseudomonas aeruginosa LasB Subverts Alveolar Macrophage Activity by Interfering With Bacterial Killing Through Downregulation of Innate Immune Defense, Reactive Oxygen Species Generation, and Complement Activation","volume":"9","author":"Bastaert","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib48","article-title":"Pseudomonas aeruginosa Elastase Contributes to the Establishment of Chronic Lung Colonization and Modulates the Immune Response in a Murine Model","volume":"11","author":"Cigana","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2025.2581889","article-title":"Unraveling the immunosuppressive role of Elastase B produced by cystic fibrosis isolates of Pseudomonas aeruginosa in an organotypic 3D lung epithelial cell model","volume":"16","author":"Wauters","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.ymthe.2026.06.029_bib50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.drudis.2021.02.026","article-title":"Pseudomonas aeruginosa elastase (LasB) as a therapeutic target","volume":"26","author":"Everett","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.06.029_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1139\/cjm-2013-0667","article-title":"Elastase LasB of Pseudomonas aeruginosa promotes biofilm formation partly through rhamnolipid-mediated regulation","volume":"60","author":"Yu","year":"2014","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.7754\/Clin.Lab.2018.180331","article-title":"Relationship Among Antibiotic Resistance, Biofilm Formation and lasB Gene in Pseudomonas Aeruginosa Isolated from Burn Patients","volume":"64","author":"Roshani-Asl","year":"2018","journal-title":"Clin. Lab."},{"key":"10.1016\/j.ymthe.2026.06.029_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chom.2015.10.013","article-title":"Filamentous Bacteriophage Promote Biofilm Assembly and Function","volume":"18","author":"Secor","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2026.06.029_bib54","doi-asserted-by":"crossref","first-page":"7986","DOI":"10.4049\/jimmunol.174.12.7986","article-title":"Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen1","volume":"174","author":"Santosuosso","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib55","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4049\/jimmunol.178.4.2387","article-title":"Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization","volume":"178","author":"Santosuosso","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib56","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","article-title":"Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2","volume":"185","author":"Afkhami","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.029_bib57","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1128\/IAI.00717-16","article-title":"Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa","volume":"84","author":"Bayes","year":"2016","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2026.06.029_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/2049-632X.12043","article-title":"The responses of \u03b3\u03b4 T-cells against acute Pseudomonas aeruginosa pulmonary infection in mice via interleukin-17","volume":"68","author":"Liu","year":"2013","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.ymthe.2026.06.029_bib59","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.3390\/ijms23158427","article-title":"Pseudomonas Aeruginosa Lung Infection Subverts Lymphocytic Responses through IL-23 and IL-22 Post-Transcriptional Regulation","volume":"23","author":"Villeret","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.029_bib60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.coi.2013.03.011","article-title":"Th17 cell based vaccines in mucosal immunity","volume":"25","author":"Kumar","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.029_bib62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ymthe.2021.08.007","article-title":"IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa infections","volume":"30","author":"Kheir","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.029_bib63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/microorganisms11040916","article-title":"Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials","volume":"11","author":"Elmassry","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.ymthe.2026.06.029_bib64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/15412555.2021.2000957","article-title":"Prevalence, Pattern, Risks Factors and Consequences of Antibiotic Resistance in COPD: A Systematic Review","volume":"18","author":"Smith","year":"2021","journal-title":"COPD"},{"key":"10.1016\/j.ymthe.2026.06.029_bib65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.029_bib66","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/104303401750270913","article-title":"Cross-strain protection against clinical and laboratory strains of Pseudomonas aeruginosa mediated by dendritic cells genetically modified to express CD40 ligand and pulsed with specific strains of Pseudomonas aeruginosa","volume":"12","author":"Kikuchi","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.029_bib67","doi-asserted-by":"crossref","first-page":"e0039621","DOI":"10.1128\/IAI.00396-21","article-title":"Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection","volume":"89","author":"Peng","year":"2021","journal-title":"Infect. Immun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600506X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600506X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:19:17Z","timestamp":1788362357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600506X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S152500162600506X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.029","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17\/IgA mucosal Immunity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}